Float Secures $10M to Bring Specialty Care Home for Chronic Conditions
Float, a healthcare marketplace focused on delivering in-home care for chronic illnesses, has secured $10M in Series A funding led by...
Stay updated with breaking news from Andrew Bartynski. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Float, a healthcare marketplace focused on delivering in-home care for chronic illnesses, has secured $10M in Series A funding led by...
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
Share this article BOSTON, Jan. 6, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced that on December 31, 2020 it acquired ANA Therapeutics, a privately held biotechnology company developing ANA-001, a proprietary capsule formulation of niclosamide for coronavirus indications, currently in Phase 2/3 clinical trials as a treatment for COVID-19. The transaction was unanimously approved by both the NeuroBo Pharmaceuticals' and ANA Therapeutics' Boards of Directors. "This is an exciting and transformative acquisition for ...